UNSPSC 51162716: Guaiacol butyrate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C11H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48936E6FTM, chemically known as butanoic acid, 2-methoxyphenyl ester but more generally known as guaiacol butyrate, which bears US NIH Compound Identifier 77756. Most nations, for tariff and trade purposes, schedule guaiacol butyrate under HS 29095000. As of Q4 2014, GUAIACOL BUTYRATE remains US FDA's Preferred Term for this commodity. SMILES: CCCC(=O)OC1CCCCC1OC.

UNSPSC 51162716 Guaiacol butyrate, a Commodity code, nominally describes a specific organic compound, but recent state and local procurement activity under this code shows little alignment with that chemical classification. The two opportunities tagged to this code instead solicit naloxone and safe drug deactivation systems (Seminole County, Florida) and multi-source generic pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). These solicitations represent pharmaceutical and medical supply procurement rather than guaiacol butyrate itself, signaling a potential classification mismatch in how issuing bodies have tagged their opportunities. The work being transacted involves acquisition of health and emergency-response medications and products through both direct county procurement and statewide cooperative contracting mechanisms.

The issuing bodies include a county health department (Seminole County, Florida) and a state-administered multistate cooperative purchasing alliance serving participating state and local government facilities across multiple states including Oregon. Geographically, recent activity concentrates in Florida and the Upper Midwest (Minnesota), with the MMCAP cooperative spanning a broader footprint across participating states. The Seminole County opportunity (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, requiring vendors to include shipping and delivery costs and comply with E-Verify and federal compliance standards. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with awarded vendors effective July 1, 2026, requiring cGMP certification, DSCSA compliance, and contractual relationships with authorized wholesalers, with price competitiveness weighted at 75 percent of the evaluation.